NEW YORK,
June 17,
2024 /PRNewswire/ --
UNITED STATES
DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA
In re Talis Biomedical Corporation
Securities
Litigation
|
Case No. 22-cv-00105-SI
|
SUMMARY NOTICE OF PENDENCY
OF CLASS ACTION
To:
All persons or entities that purchased or otherwise acquired
common stock issued by Talis pursuant and/or traceable to
the registration statement and prospectus issued in connection with
the Company's February 11, 2021 initial public offering
between February 11, 2021 and
August 11, 2021, inclusive, and were
damaged thereby.
YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal
Rules of Civil Procedure and an Order of the United States District Court for the
Northern District of California
that the above-captioned action (the "Action") has been certified
to proceed as a class action on behalf of the Class as defined
above.
The Action alleges that Defendants Talis
Biomedical Corporation ("Talis") and certain of its current and
former officers and directors ("Defendants") made false and
misleading statements and material omissions concerning Talis
One in violation of the Securities Act of 1933. Defendants deny all
of these allegations and deny any wrongdoing or violation of
law. Please note: at this time, there is no judgment,
settlement, or monetary recovery.
IF YOU ARE A MEMBER OF THE CLASS, YOUR RIGHTS WILL BE AFFECTED
BY THIS ACTION. Additional information about the Action and access
to important documents, including, but not limited to, a long-form
Notice of Pendency of Class Action that more fully sets forth
your rights in this Action, the operative pleadings, and the Court
Order certifying the above- referenced Class, is available at
www.TalisSecuritiesLitigation.com or by contacting the Notice
Administrator at:
Talis
Biomedical Corporation Securities Litigation
c/o A.B.
Data, Ltd., PO Box 173064
Milwaukee, WI 53217
1-877-331-0411
info@TalisSecuritiesLitigation.com
Inquiries may also be made to the following representatives of Class
Counsel:
Evan A. Kubota
BLEICHMAR FONTI & AULD LLP
300 Park Avenue, Suite 1301 New York,
NY 10022
1-888-879-9418
If you are a Class Member, you have the right to decide whether
to remain a member of the Class. If you want to remain a member of
the Class, you do not need to do anything at this time other than
to retain your documentation reflecting your transactions and
holdings in Talis common stock. Pursuant to Federal
Rule of Civil Procedure 23(c)(3), if you are a Class
Member and do not exclude yourself from the Class,
you will be bound by the proceedings in this
Action, including all past, present, and future orders and
judgments of the Court, whether favorable or unfavorable.
If you ask to be excluded from the Class, you will not be bound
by any order or judgment of this Court in this Action; however, you
will not be eligible to receive a share of any money which might be
recovered for the benefit of the Class. To exclude yourself from
the Class, you must submit a written request for exclusion
by no later than August 20,
2024, in accordance with the instructions set
forth in the long-form Notice available at
www.TalisSecuritiesLitigation.com.
Further information regarding this Notice may be obtained by
visiting the case website above.
PLEASE DO NOT CONTACT THE COURT REGARDING
THIS NOTICE.
BY ORDER OF THE COURT:
Judge Susan Illston
United States District Judge United States District Court for the
Northern District of California
View original
content:https://www.prnewswire.com/news-releases/bleichmar-fonti--auld-llp-announces-the-notice-of-pendency-of-class-action-in-the-in-re-talis-biomedical-corporation-securities-litigation-302172297.html
SOURCE Bleichmar Fonti & Auld LLP